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Abstract
Autophagy is a tightly controlled process comprising lysosomal degradation and recycling of cellular proteins and organelles. 
In cancer, its paradoxical dual role of cytoprotection and cytotoxicity is context-dependent and controversial. Autophagy 
primarily acts as a mechanism of tumour suppression, by maintenance of genomic integrity and prevention of proliferation 
and inflammation. This, combined with immune-surveillance capabilities and autophagy’s implicated role in cell death, acts 
to prevent tumour initiation. However, established tumours exploit autophagy to survive cellular stresses in the hostile tumour 
microenvironment. This can lead to therapy resistance, one of the biggest challenges facing current anti-cancer approaches. 
Autophagy modulation is an exciting area of clinical development, attempting to harness this fundamental process as an 
anti-cancer strategy. Autophagy induction could potentially prevent tumour formation and enhance anti-cancer immune 
responses. In addition, drug-induced autophagy could be used to kill cancer cells, particularly those in which the apoptotic 
machinery is defective. Conversely, autophagy inhibition may help to sensitise resistant cancer cells to conventional chemo-
therapies and specifically target autophagy-addicted tumours. Currently, hydroxychloroquine is in phase I and II clinical 
trials in combination with several standard chemotherapies, whereas direct, deliberate autophagy induction remains to be 
tested clinically. More comprehensive understanding of the roles of autophagy throughout different stages of carcinogenesis 
has potential to guide development of novel therapeutic strategies to eradicate cancer cells.
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Atg genes  Autophagy-related genes
mTOR  Mammalian target of rapamycin
PI3K  Phosphatidylinositol-3-kinase
ROS  Reactive oxygen species
DDA  Dendrogenin A
LXR  Liver X receptor
LC3  Microtubule-associated protein 1A/1B-light 
chain 3
TFEB  Transcription factor EB
TAMR  Tamoxifen-resistant
HDAC  Histone deacetylase
SAHA  Suberoylanilide hydroxamic acid
GBM  Glioblastoma multiforme
V600E  Valine to glutamic acid mutation at amino 
acid 600 of BRAF
SERM  Selective oestrogen receptor modulator
ER  Oestrogen receptor
FDA  Food and drug administration
Introduction
Autophagy is a highly conserved process of catabolism, 
which recycles and degrades intracellular components, 
primarily as a mechanism of cellular survival [1]. It was 
first revealed in 1949 by Christian de Duve following the 
discovery of lysosomes and their functions [2]. In eukary-
otic cells, there are three types of autophagy known as 
macroautophagy, microautophagy and chaperone-medi-
ated autophagy [3]; the majority of our understanding is 
of macroautophagy (referred to as autophagy from here 
onwards). Basal autophagy is fundamental to cellular 
(metabolic and genetic) homeostasis, involved in quality 
control of proteins and organelles in the cellular environ-
ment [4]. In stressful environments and under starvation 
conditions, autophagy can also be induced to sustain 
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metabolic demands, by producing substrates required for 
cell survival, and maintain genomic integrity.
Autophagy is a tightly controlled process, influenced 
by multiple signalling pathways. Autophagy-related genes 
(Atg genes) orchestrate the formation of the autolysosome, 
through a series of sequential steps: initiation, nucleation, 
elongation and maturation [5, 6]. Figure 1 highlights some 
of the key genes and signalling molecules involved in the 
process and depicts the process of phagosome formation 
and lysosomal degradation. The mammalian target of rapa-
mycin (mTOR), a downstream protein in the phosphati-
dylinositol-3-kinase (PI3K) cascade, is the main inhibitor 
of autophagy, preventing its execution when nutrients are 
abundant [7]. Conversely, the initiation factor eiF2a senses 
nutrient depletion and activates the process to provide cel-
lular substrates including fatty acids and amino acids [8].
Autophagy has dual, apparently paradoxical roles in 
cytoprotection and cytotoxicity. Preventing the accu-
mulation of damaged proteins or organelles protects the 
cell from oxidative stress and subsequent DNA damage, 
however, if autophagy is extensive and excessive, this can 
lead to cellular destruction termed type II programmed 
cell death [6]. Autophagy activation and dysregulation has 
implications in disease pathogenesis including type II dia-
betes, cardiovascular and neurological disorders, microbial 
infections and cancer [6]. The role autophagy plays in can-
cer is controversial with evidence that autophagy plays a 
part in both suppressing and promoting tumourigenesis. 
More comprehensive understanding of its functions could 
provide a novel approach to cancer treatment, by providing 
new strategies to modulate this process in a therapeutic 
arena.
Autophagy: a role in tumour suppression
A large body of evidence suggests autophagy primarily acts 
as a tumour suppressive mechanism. For example, Ras-
driven epithelial tumourigenesis is suppressed by autophagy 
by limiting accumulation of reactive oxygen species (ROS) 
[9]. Commonly mutated oncogenes repress autophagy, 
whereas tumour suppressors work to activate the process 
[10]. Beclin1 is a mammalian autophagy-related protein, key 
in the initiation and nucleation processes [10, 11]; beclin-1 
gene is monoallelically deleted in 40–75% of breast, ovarian 
and prostate cancers and has reduced expression in human 
breast carcinoma lines [11, 12]. Additionally, heterozygous 
mice are prone to the development of spontaneous tumours 
including lung, liver carcinomas and lymphomas [11]. 
Reduced expression of beclin1 protein has also been shown 
in a variety of brain tumours, cervical and hepatocellular 
carcinoma and colorectal cancer cell lines [13–16]. Unsur-
prisingly, beclin1 has been proposed as a candidate tumour 
suppressor gene, with its disruption likely to be ‘mechanisti-
cally key’ in tumourigenesis [1].
Deletion of Atg 5 and Atg7 causes spontaneous formation 
of benign liver tumours [17], further suggesting a role for 
autophagy in tumour suppression. Atg5 and beclin 1 have 
been shown to act as ‘guardians’ of the cellular genome, 
by preventing DNA damage, aneuploidy and amplification 
Fig. 1  The genetic background and steps of autophagy. ULK1 phos-
phorylation status is critical to autophagy initiation. Once activated, 
it forms a complex with Atg13 and FIP200, which further activates 
beclin1. Beclin1 activation completes initiation and is central to the 
nucleation process. Subsequently, LC3B complexes with the Atg sys-
tem, which elongates the isolation membrane to form the autophago-
some. Lysosomal fusion is central to the maturation process to pro-
duce the autolysosome. This is responsible for the degradation and 
recycling of intracellular components to substrates such as amino 
acids and fatty acids, which can be used for cell growth. mTOR and 
eIF2a are the two main cellular sensors which control the status of 
autophagy: mTOR inhibits the process, whereas eIF2a activates it
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[1, 18]. Furthermore, tumours with mono- or biallelic loss 
of these genes display increased tumourigenicity [18]. 
Autophagy-deficient yeast display a similar phenotype 
with an increase in mitochondrial mutations; this suggests 
that autophagy turnover acts to eradicate cells possessing 
DNA damage, preventing persistence of mutations [19, 20]. 
Although not fully understood, it provides evidence that 
autophagy dysregulation may cause (or at least contribute to) 
genomic instability, acquisition of which drives evolution of 
multiple cancer hallmarks enabling tumour promotion [21].
The mammalian proteins p62 and NBR1 selectively 
undergo autophagic degradation and can act as cargo recep-
tors, or adaptors for autophagy of ubiquitinated substrate 
targets [22]. A key role for p62-mediated autophagy has 
been implicated in tumourigenesis; in a state of autophagic-
deficiency, p62 may accumulate (Fig. 2) [4]. P62 activates 
oncogenic signalling cascades involving NFkB and NRF2, 
both of which are able to drive tumour formation [23, 24]. 
The role of p62 has also been explored in mouse models, 
whereby accumulation is coupled with a state of chronic 
inflammation and tissue damage, for example, as shown in 
the liver and pancreas [23, 25]. p62 also promotes tumour 
initiation by causing mitochondrial defects, increasing oxi-
dative stress and subsequent DNA damage [4]. This presents 
a setting whereby autophagy can work to diminish metabolic 
stress and prevent pro-tumourigenic events from occurring.
Autophagy: a role in immune surveillance
As alluded to, autophagy also has a tumour suppressive 
role in established cancer cells. Autophagy is critical for 
optimal immune function, indeed many studies have shown 
autophagy to be essential for the recruitment of immune cells 
to the tumour bed, including dendritic cells and cytotoxic T 
lymphocytes, which are key in the stimulation of anti-cancer 
immune responses [26, 27]. Indeed, inhibition of autophagy 
has been shown to lead to inhibition of the immune system, 
tumour immune escape and development [28]. Autophagy 
generates extracellular ATP which is thought to be the mech-
anism behind immune cell recruitment. Further supporting 
this thesis, autophagy inhibition promotes ATP degradation 
to adenosine, which facilitates accumulation of anti-immune 
T regulatory cells [29]. Immune competency has been shown 
to increase sensitivity in both radiotherapy and chemother-
apy-treated cancer cells [27, 30, 31]. For malignant cells 
to survive and tumours to progress require escape from 
immune detection. Novel anti-cancer regimens are being 
explored, involving autophagy induction that re-establishes 
immune surveillance. Nutrient deprivation or caloric restric-
tion mimetics reduce lysine acetylation of cellular proteins, 
triggering autophagy. Short-term fasting, or autophagy-
inducing caloric restriction mimetics have been shown to 
enhance chemotherapeutic efficacy (of mitoxantrone and 
oxaliplatin) [29, 31].
Thus, it may be argued that activating autophagy might be 
a relevant clinical objective to enhance anti-tumour immune 
surveillance, and potentially increase the efficacy of current 
conventional therapies.
Cytotoxic autophagy
Autophagy also acts in a tumour suppressive manner via 
its capacity to induce cell death. Autophagic cell death is 
referred to as type II programmed cell death and is charac-
terised by the presence of cytoplasmic vacuolisation, with 
increased autophagic flux. Unlike apoptosis, autophagic 
cell death occurs independently of caspase activity [6, 26]; 
it lacks the tissue inflammatory response associated with 
necrosis, which may otherwise promote tumour formation 
[32]. Autophagic cell death is commonly seen throughout 
embryogenesis [33, 34], but is not restricted to developmen-
tal stages of life. In differentiated tissues, tumour suppres-
sive autophagy has been observed: dendrogenin A (DDA), a 
newly discovered cholesterol metabolite found in mammals, 
possesses tumour cell differentiation and tumour suppressive 
Fig. 2  Autophagic mechanisms of tumour suppression. Autophagy 
deficiency can cause the accumulation of P62 which subsequently 
drives tumour initiation. P62 can activate oncogenic signalling path-
ways to stimulate cellular proliferation, as well as increasing oxida-
tive stress and inflammation. In turn, this can lead to genomic insta-
bility and chronic tissue damage, promoting spontaneous tumour 
formation
 Cancer Chemotherapy and Pharmacology
1 3
properties in breast cancers, melanoma and acute myeloid 
leukaemia (AML), including primary AML patient samples 
[34, 35]. Metabolic studies demonstrated reduced DDA lev-
els in cancer cells and human tumours compared to nor-
mal cells and tissues [35, 36]. In vitro and in vivo, DDA 
triggers tumour cytotoxic autophagy by binding to the liver 
x receptor (LXR), a nuclear receptor, and by inducing the 
transcriptional expression of pro-autophagic factors such as 
LC3b, Nur77, NOR1 and TFEB [34]. Interestingly, TFEB 
is a transcription factor and master gene-controlling lysoso-
mal biosynthesis and autophagy. Moreover, by inhibiting the 
D8D7I subunit of the cholesterol epoxide hydrolase enzyme 
(ChEH), DDA induces accumulation of sterols which con-
tribute to increased formation of lysosomes—essential com-
ponents of the autophagy machinery [34]. Thus, the nuclear 
receptor LXR has been identified as an essential molecular 
target activating lethal autophagy in cancers, and the com-
bined action of DDA on LXR and D8D7I most likely con-
tributes to its high efficacy by triggering sustained lethal 
autophagy, which is not observed with prototypical ChEH/
D8D7I inhibitors or other LXR agonists [36, 37]. The anti-
tumour activity and low-toxicity of DDA support the clinical 
development of DDA.
A variety of clinical anti-cancer therapies have been 
reported to induce cytotoxic autophagy including resveratrol 
[38], arsenic trioxide [39], and tamoxifen [6, 40], suggest-
ing autophagy directly contributes to the cytotoxic effects 
of these drugs. However, the relationship between steroid 
biogenesis, tamoxifen and autophagy are complex—as will 
be discussed, autophagy may contribute to tamoxifen-resist-
ance. In tamoxifen-resistant MCF-7 (TAMRMCF-7) cells, 
caspase-independent autophagic cell death has been induced 
by the histone deacetylase (HDAC) inhibitor suberoylanilide 
hydroxamic acid (SAHA). Significantly decreased HDACs 
1, 2, 3, 4, 7 and enhanced acetylation of histones 3 and 4 
accompanied expression of autophagic markers LC3-II and 
beclin-1 [41]. In mice-bearing TAMRMCF-7 xenografts, 
SAHA significantly reduced tumour growth without side 
effects. Authors concluded that SAHA-mediated autophagic 
cell death offers a promising strategy for treatment of tamox-
ifen-resistance breast cancer. Finally, the alkylating agent 
temozolomide, used in standard of care chemotherapy for 
glioblastoma multiforme (GBM) has been shown to induce 
autophagic cell death in apoptosis-resistant GBM models 
(Fig. 3) [42]. Subsequent inhibition of the autophagy-related 
genes beclin1 and Atg5 has been shown to reduce cell death, 
Fig. 3  Induction of autophagy 
by temozolomide in U87MG 
GBM cells (100 µM; 72 h). 
a Accumulation of acidic 
vesicular organelles; b detection 
of autophagosomes—double-
membrane vacuoles; c inhibi-
tion of temozolomide-induced 
autophagy resulting in cell 
death by apoptosis [42]
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further supporting this cytotoxic role in a cancerous setting 
[43].
Autophagy induction
Although there have currently been no attempts to directly 
induce autophagy in cancer models, modulation of this pro-
cess could comprise a new anti-cancer strategy in the future 
[44]. The role of autophagy in preventing tumour initiation 
has been well-researched and forms an opportunity to har-
ness this process. Autophagy induction could be beneficial 
in deficient or mutated pre-cancerous cells, by way of pre-
venting tumour initiation. Autophagy induction could help 
to reduce the accumulation of p62, particularly in tissues 
where chronic inflammation is known to be an evolutionary 
pre-cursor to cancer. In the future, p62 could be used as a 
biomarker to indicate autophagy deficiencies and identify 
patients who may benefit from autophagy induction [45]. 
Additionally, autophagy confers immunogenic properties 
in existing tumour cells, thus it is pertinent to test whether 
induction can stimulate anti-cancer immune responses and 
increase cancer cell sensitivity to conventional therapies.
To summarise, it is of clinical interest to investigate fur-
ther whether autophagy induction can be exploited to pre-
vent tumour initiation, reduce tumourigenicity in established 
cancers, enhance efficacy, or mediate cytotoxicity of chemo-
therapy. Observations have also indicated that induction of 
autophagic cell death may provide an attractive therapeutic 
strategy, particularly in cancer cells able to evade apoptosis, 
which is a common hallmark of many cancers [11].
A deeper understanding of the process of lethal 
autophagy, and how molecular mechanisms interact with 
other cell death pathways, will be crucial in the development 
of effective strategies to accomplish cancer cell toxicity.
Controversy
Although autophagy has been widely implicated as a 
form of cell death, controversy remains concerning the 
extent of its actions. It is possible that autophagy is merely 
associated with dying cells and not a direct cause of the 
toxic fate. Indeed, autophagic tumour cell death has only 
been reported in very few circumstances and instead has 
been shown to activate alternative mechanisms executing 
cell death [33, 46]. It has been postulated that autophagic 
association could represent an adaptive response, a failed 
attempt at cell survival [6]. Targeting this process in vivo 
could prove highly challenging, as multiple checkpoints 
prevent type II cell death from occurring [44]. Autophagy 
has also been described as a mechanism of tumour pro-
motion, thus fully understanding the context in which 
autophagy occurs will be critical before developing any 
induction-based therapies, which could conversely support 
tumourigenicity.
Autophagy: a role in tumour promotion
Although autophagy has been shown to act in a tumour sup-
pressive manner, its role is context-dependent; once tumours 
are established, they can exploit this process to enable sur-
vival. This paradoxical change from tumour suppressor to 
tumour promoter has been termed the ‘autophagy switch’ 
[47]. Cancer cells can use autophagy to survive the hostile 
metabolic microenvironment, utilising autophagic substrates 
to sustain tumour growth and maintain cellular fitness.
Autophagy promotes tumourigenesis by providing an 
escape mechanism to cellular stresses. Within the tumour 
microenvironment, cancer cells experience harsh conditions 
including hypoxia and acidity. Cytoprotective autophagy 
provides a mechanism to promote cancer cell survival, 
removing otherwise toxic proteins and providing cellular 
substrates to sustain growth [46]. Hypoxic regions have 
shown elevated levels of autophagy, recycling organelles 
such as ribosomes and mitochondria, allowing resulting 
catabolites to fuel biosynthesis and energy metabolism—
maintaining cancer cell viability [6, 48, 49].
Autophagy is robustly activated in tumour cells by can-
cer-associated stressors such as growth factor deprivation 
and hypoxia. In the majority of cases, autophagy induc-
tion promotes survival in response to stress (as will be 
exemplified); survival by autophagy becomes dangerous if 
apoptosis is disabled—resulting in quiescence/dormancy 
of tumour cells. Hypoxia and glucose deprivation (condi-
tions rife within the tumour microenvironment) upregulate 
autophagy—enabling survival. Autophagosomes are most 
evident in tumour cells of hypoxic regions, and deletion 
of autophagy-regulating genes has been shown to result in 
tumour cell death especially in hypoxic regions, strongly 
indicating that cancer cells exploit autophagy to survive and 
promote tumourigenesis [18]. A role for autophagy in pro-
motion of a carcinoma fate is further supported by observa-
tions of malignant adenoma formation in autophagy-com-
petent cells [17]. Other mouse models have demonstrated 
the role of autophagy in the development of a carcinoma 
phenotype and have shown autophagy inhibition to reduce 
tumour volume [6, 17]. A link between autophagy and p53 
suppression has been proposed, which could underlie this 
tumour-promoting background in some circumstances [50]. 
Robust evidence supports the argument that inhibition of 
autophagy, as a therapeutic strategy could serve to reduce 
tumour aggression and promote a more benign, ‘treatable’ 
state [4].
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Autophagy addiction
Certain tumour types have shown elevated levels of 
autophagy, thus ‘autophagy addiction’ has been pro-
posed as a form of tumour maintenance or promotion [4]. 
Tumours harbouring Ras and RAF mutations lie in this 
category. Ras-mutated tumours have shown an increased 
dependency on the autophagic process in vitro and in vivo, 
and knockdown of autophagy-related genes Atg5 and Atg7 
limited tumour growth [6, 51, 52]. Ras mutations can 
cause a metabolic depletion of cellular energy sources; 
thus, autophagy can enable cell survival by preserving 
mitochondrial integrity and directly providing substrates 
required for cell growth [53]. It has been suggested that the 
role of autophagy in this setting is intrinsically connected 
to the status of p53. Autophagy has been shown to inhibit 
this tumour suppressor gene to accelerate tumourigenesis 
of mutant Ras tumours [51, 54]. Autophagy addiction 
has also been implicated in a specific metabolic context; 
autophagy-competent cells have an increased glycolytic 
capacity and show elevated levels of glycolysis. Inhibition 
of autophagy attenuates proliferation and reduces this met-
abolic alternative [55]. Together, these autophagic activi-
ties facilitate Ras-driven transformation, summarised in 
Fig. 4.
Pancreatic tumours typically harbour Ras mutations 
and frequently show constitutive levels of autophagy [6]. 
Genetic and chemical modes of autophagy inhibition have 
caused significant tumour regression of pancreatic cancer 
cells in vitro [56]. RAF-mutated tumours have also dem-
onstrated increased dependency on autophagy to sustain 
tumour growth [57]. V600E mutations, characteristic of 
melanoma, exploit autophagy to preserve mitochondrial 
function and reduce oxidative stress [44, 57]. Autophagy 
competency in tumour cells is likely to confer a selective 
advantage, providing a mechanism of survival to withstand 
cellular stresses. Ras or RAF-driven tumours typically 
have a poor prognosis due to their aggressive nature [52]; 
thus, fully understanding the role of autophagy-depend-
ency in this context could provide a novel therapeutic 
strategy to target these tumours.
Autophagy‑mediated drug resistance 
and cancer cell survival
In addition to its role in tumour promotion and survival in 
hostile environments, autophagy has also been implicated 
in resistance to conventional anti-cancer therapies, another 
form of stress imposed on cancer cells [54]. Returning 
to tamoxifen, autophagy`s role in resistance to this (and 
other) selective oestrogen receptor modulators (SERMs) 
has been revealed. Tamoxifen is commonly used in the 
treatment of oestrogen receptor positive (ER+; the most 
frequent subtype) breast cancer; however, treatment failure 
resulting from acquired resistance to tamoxifen is often 
observed. De Medina et al. [58] established that sterol-
dependent macroautophagy induced by tamoxifen may 
be associated with cell survival rather than cytotoxicity; 
inhibition of autophagy (by 3-methyl adenine or bafilomy-
cin) sensitised cells to tamoxifen and other SERMs [33]. 
Tamoxifen competitively binds not only to the ER, but 
also to microsomal antioestrogen binding sites compris-
ing cholesterol-5,6-epoxide hydrolase enzymes involved 
in cholesterol biosynthesis. SERMs including tamoxifen 
inhibit these enzymes leading to accumulation of sterol 
precursors—triggering autophagic survival [59]. By delay-
ing apoptosis or DNA damage mechanisms, autophagy can 
be viewed as an adaptive response to promote the sur-
vival of the targeted tumour cells [29, 49, 60]. It has also 
been postulated that autophagy enables cancer cells to 
adopt a dormant state [18, 61]. Dormancy can ultimately 
lead to relapse and re-growth of cancer cells to facilitate 
their long-term survival. The underlying mechanisms 
of therapy resistance and tumour cell dormancy are not 
Fig. 4  Autophagic mechanisms of tumour promotion. Increased 
oncogenic signalling present in established tumours can exploit 
autophagy to sustain tumour growth and survival. Uncontrolled pro-
liferation leads to increased metabolic demands and cellular stress; 
autophagy can provide cells with substrates for growth, inhibit 
tumour suppressive functions of p53 and increase metabolic and gly-
colytic functions of cancer cells
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yet comprehensively understood but are likely to involve 
a state of cellular senescence, mediated by autophagy 
[26]. Molecular understanding of the functional roles 
of autophagy in tumour maintenance and resistance to 
environmental and external stresses will guide targeting 
autophagy. Indeed, evidence accumulates appearing to jus-
tify the development of autophagy inhibitors as a strategy 
in cancer therapy.
Clinical developments: autophagy inhibition 
therapies
All autophagy modulating drugs in clinical trials are inhibi-
tors of the process, primarily seeking to increase tumour sen-
sitivity to conventional therapies [29]. It is widely accepted 
that autophagy inhibition could help sensitise cancer cells 
to cytotoxic therapies and potentiate the effects of current 
treatments in the clinic.
Chloroquine and its derivatives, previously used as anti-
malarial agents, are leading the field and are currently the 
only FDA-approved modulators of autophagy [62]. Pre-clini-
cal evidence has demonstrated the effectiveness of inhibiting 
autophagy to enhance chemotherapy cytotoxicity; this has 
been achieved either as a monotherapy or in combination 
with current chemotherapeutic drugs [62]. Chloroquine and 
its derivatives limit the acidification of lysosomes to inhibit 
their role in autophagic degradation [62–64]. Hydroxychlo-
roquine is the preferred analogue because of its enhanced 
potency and limited side effects; the current phase I and 
phase II clinical trials in place involving hydroxychloroquine 
in combination with a variety of anti-cancer agents possess-
ing different modes of action and used to treat distinct cancer 
phenotypes are detailed in Table 1 [46, 62, 65].
Although clinical trials for hydroxychloroquine appear 
promising in both solid and haematological malignancies, 
the requirement for more specific and potent inhibitors 
remains. Lys05, a bisaminoquinoline derivative of chlo-
roquine (Fig. 5a), has led to more pronounced lysosomal 
Table 1  Current autophagy inhibitors in clinical trials
There are several phase I and phase II clinical trials for hydroxychloroquine in combination with many anti-cancer treatments in different cancer 
phenotypes [46, 62, 65]
Drug 1 Drug 1 Mode of action Phase
HCQ As a single agent ER + breast cancer I
HCQ As a single agent Prostate cancer II
HCQ Sunitinib Tyrosine kinase inhibitor Adult solid neoplasm I
HCQ Vorinostat Histone deacetylase inhibitor Malignant solid tumour I
HCQ Vorinostat Histone deacetylase inhibitor Colorectal cancer I/II
HCQ Vorinostat/sirolimus Histone deacetylase inhibitor/mTOR inhibitor Advanced cancers I
HCQ MKK0226 Akt inhibitor Advanced cancers I
HCQ Gemcitabine Anti-metabolite Advanced adenocarcinoma I/II
HCQ Gemcitabine/carboplatin Anti-metabolite/alkylating agent Small cell lung cancer I/II
HCQ Interleukin-2 Immune modulator Renal cell carcinoma I/II
HCQ Capecitabine Anti-metabolite Pancreatic carcinoma II
HCQ Abraxane and gemcitabine Anti-microtubule agent/anti-metabolite Pancreatic carcinoma II
Fig. 5  Structures of autophagy 
inhibitors: a Lys05; b verte-
porfin
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accumulation and deacidification resulting in impaired 
autophagy and tumour growth inhibition; moreover, single 
agent antitumor activity was observed without toxicity [66]. 
Mice were observed to develop an intestinal phenotype 
resembling that of mice and humans with genetic defects in 
the autophagy gene Atg16L1. Together these data provide 
evidence that Lys05 targets autophagy, and validate the ther-
apeutic potential of this agent [64, 67]. Verteporfin (Fig. 5b) 
is another novel drug which acts at an earlier stage of the 
process to prevent initial formation of the autophagosome. 
In combination with the anti-metabolite gemcitabine, verte-
porfin has been shown to reduce pancreatic tumour growth 
in a pre-clinical setting [68]. This highlights the fact that 
autophagy inhibition can be targeted at multiple stages of 
the process. It can thus be argued that autophagy modula-
tion presents an attractive therapeutic concept, particularly 
in regards to potentiation of anti-tumour activity and sensi-
tisation of therapy-resistant tumours.
Summary
To summarise, increasing our understanding of the processes 
of autophagy and its roles in different stages of cancer will 
underpin developments in this field. Evidence primarily sup-
ports autophagy as a tumour suppressive mechanism, with 
autophagy-related genes commonly deleted or defective in 
different cancer types. Autophagy suppresses tumour initia-
tion by preventing inflammation and oncogenic proliferation. 
Maintenance of genomic stability is also a key property of 
autophagy tumour suppression and is most likely achieved 
by the prevention of damaged mitochondrial accumulation 
and subsequent generation of oxidative stress. Autophagy 
and immune-surveillance are intimately linked to prevent 
tumourigenesis. As an alternative form of programmed cell 
death, autophagy has been implicated as a mechanism of 
cytotoxicity in current anti-cancer treatments.
Thus, it is of therapeutic interest to induce autophagy 
to enhance tumour prevention or elimination. Such a strat-
egy could be beneficial in patients with increased risk of 
developing cancer, particularly in cancer types with known 
and defined pre-cancerous evolution. Identifying biomark-
ers, such as p62, could help to identify autophagy-deficient 
patients who would best respond to this form of treatment.
Inducing autophagy in apoptosis-resistant cells could 
provide an alternative route of controlled cancer cell death, 
which could be crucial in surmounting therapy resistance. 
Furthering our understanding of the interactions between 
apoptosis, autophagy and other forms of cell death will be 
the key in developing alternative mechanisms towards target-
ing cancer cell toxicity.
The elusive autophagic switch from tumour suppres-
sor to tumour promoter is evident once tumours are 
established. Cancer cells exploit autophagy to sustain 
increased metabolic demands and survive under various 
stresses including hypoxia, acidity and anti-cancer thera-
pies. This poses one of the key challenges in the clinic: 
therapy resistance. With this in mind, autophagy inhibi-
tion poses an attractive therapeutic strategy, with clini-
cal advances already taking place using a combinatorial 
approach with hydroxychloroquine in phase I and II tri-
als. The important role of autophagy in the anti-cancer 
immune response must also be considered; autophagy 
inhibition could be combined with immune-stimulatory 
drugs, such as checkpoint inhibitors, to prevent immune 
down-regulation [69]. It is anticipated in the future that 
autophagy inhibition may help to sensitise resistant cancer 
cells to conventional therapies already in place. Specific 
cancer types which are ‘autophagy-addicted’ are most 
likely to benefit from autophagy inhibitors, indicating the 
potential wide application of these drugs.
To conclude, the role of autophagy in cancer is com-
plex, context-dependent and far from fully elucidated.
Under normal physiology, autophagy can be a sup-
pressor of tumourigenesis—a mean of ridding the body 
of damaged cells and ‘recycling’ nutrients. There is a 
role for autophagy in immune-surveillance and inhibi-
tion of malignant transformation; however, paradoxi-
cally, autophagy may support progression of established 
tumours, as the process can be subverted to ‘feed’ tumour 
cells. Autophagy may contribute to chemotherapy resist-
ance, therefore its inhibition may sensitise cancer cells 
to therapy; yet the importance of chemotherapy-induced 
cytotoxic autophagy is evident, specifically in apoptosis-
resistant tumour cells. Evidence supporting each of these 
statements has been discussed in this review and must be 
considered if, or when autophagy is to be exploited in 
a therapeutic setting. Fully understanding the autophagic 
switch will help to expose novel targets and mechanisms 
to target cancer cells.
In the future, it is likely that autophagy modulation will 
be specific and tailored to different cancer phenotypes, 
depending on tumour evolution and autophagy-dependency.
Today, autophagy exemplifies a controversial issue and 
an intense area of research; nevertheless, its modulation 
potentially represents an exciting novel approach in cancer 
treatment.
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